Brought to you by

Zai Lab signs agreement with GSK for two anti-inflammatory assets
22 Sep 2017
Executive Summary
GlaxoSmithKline PLC licensed Zai Lab Ltd. global rights to two anti-inflammatory candidates.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement